Literature DB >> 9783351

Differential prevalence of cigarette smoking in patients with schizophrenic vs mood disorders.

A Diwan1, M Castine, C S Pomerleau, J H Meador-Woodruff, G W Dalack.   

Abstract

Rates of substance-use disorders among psychiatric patients are consistently higher than in the general population, yet there is no clear specificity to the relationship between types of substance use and psychiatric diagnoses. Cigarette smoking may represent a substance-use behavior which has greater specificity for major psychiatric diagnoses. We examined the self-reported history of cigarette smoking vs marijuana, alcohol and cocaine use among 83 male veteran psychiatric patients with primary mood (major depression or bipolar disorder; n = 20) or schizophrenic (schizophrenia or schizoaffective; n = 63) disorders. Those in the SCZ group compared to those in the AFF group were more likely to be ever-smokers (OR 8.5, 95% CI [2.2, 32.3]), and current smokers (OR 12.0%, 95% CI [3.6, 40]), independent of age differences between the groups. There were no significant differences in marijuana, alcohol or cocaine use between the two groups when age differences were controlled. Generalizability of the findings is limited by small number of subjects, male gender and veteran status; however, the significantly higher prevalence of smoking among individuals with schizophrenic disorders may support the growing evidence of linkages between the effects of nicotine and the neurobiology of schizophrenia.

Entities:  

Mesh:

Year:  1998        PMID: 9783351     DOI: 10.1016/s0920-9964(98)00045-0

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  39 in total

1.  Neurodevelopmental liabilities of substance abuse.

Authors:  Tomas Palomo; Trevor Archer; Richard J Beninger; Richard M Kostrzewa
Journal:  Neurotox Res       Date:  2002-06       Impact factor: 3.911

2.  A double-blind randomized clinical trial of different doses of transdermal nicotine patch for smoking reduction and cessation in long-term hospitalized schizophrenic patients.

Authors:  Hsing-Kang Chen; Tsuo-Hung Lan; Bo-Jian Wu
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-06-23       Impact factor: 5.270

3.  Predictors of smoking reduction outcomes in a sample of 287 patients with schizophrenia spectrum disorders.

Authors:  Bo-Jian Wu; Tsuo-Hung Lan
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2015-08-27       Impact factor: 5.270

4.  Is initiation of smoking associated with the prodromal phase of schizophrenia?

Authors:  Kaisa Riala; Helinä Hakko; Matti Isohanni; Anneli Pouta; Pirkko Räsänen
Journal:  J Psychiatry Neurosci       Date:  2005-01       Impact factor: 6.186

5.  Reward Responsiveness Varies by Smoking Status in Women with a History of Major Depressive Disorder.

Authors:  Amy C Janes; Paola Pedrelli; Alexis E Whitton; Pia Pechtel; Samuel Douglas; Max A Martinson; Ilana Huz; Maurizio Fava; Diego A Pizzagalli; A Eden Evins
Journal:  Neuropsychopharmacology       Date:  2015-02-09       Impact factor: 7.853

6.  Correlates of secondhand tobacco smoke exposure among persons with severe and persistent mental illness (SPMI) accessing community mental health services.

Authors:  Chizimuzo T C Okoli; Joy L Johnson; Leslie Malchy
Journal:  Community Ment Health J       Date:  2009-02-03

7.  Nicotine normalizes cortico-striatal connectivity in non-smoking individuals with major depressive disorder.

Authors:  Amy C Janes; Maya Zegel; Kyoko Ohashi; Jennifer Betts; Elena Molokotos; David Olson; Lauren Moran; Diego A Pizzagalli
Journal:  Neuropsychopharmacology       Date:  2018-04-19       Impact factor: 7.853

Review 8.  Mood and anxiety regulation by nicotinic acetylcholine receptors: A potential pathway to modulate aggression and related behavioral states.

Authors:  Marina R Picciotto; Alan S Lewis; Gerrit I van Schalkwyk; Yann S Mineur
Journal:  Neuropharmacology       Date:  2015-01-09       Impact factor: 5.250

9.  The nicotinic antagonist mecamylamine has antidepressant-like effects in wild-type but not beta2- or alpha7-nicotinic acetylcholine receptor subunit knockout mice.

Authors:  R L Rabenstein; B J Caldarone; M R Picciotto
Journal:  Psychopharmacology (Berl)       Date:  2006-10-03       Impact factor: 4.530

Review 10.  Treating schizophrenia symptoms with an alpha7 nicotinic agonist, from mice to men.

Authors:  Ann Olincy; Karen E Stevens
Journal:  Biochem Pharmacol       Date:  2007-07-17       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.